BioNTech (NASDAQ: BNTX) CCO discloses option and PSU equity awards

Rhea-AI Filing Summary

BioNTech SE Chief Commercial Officer Annemarie Hanekamp filed an initial Form 3 reporting derivative equity holdings. She holds an option over 8,838 ordinary shares and performance share units linked to 11,047 ordinary shares. Both awards vest in equal annual installments over four years, subject to performance conditions.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Hanekamp Annemarie

(Last) (First) (Middle)

C/O BIONTECH SE

AN DER GOLDGRUBE 12

(Street)

MAINZ GERMANY D-55131

(City) (State) (Zip)

GERMANY

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
BioNTech SE [ BNTX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	05/28/2029(1)	05/28/2035	Ordinary Shares(2)	8,838	(3)(4)	D
Performance Share Unit	05/27/2029(5)	05/27/2035	Ordinary Shares(5)	11,047	$0	D

Explanation of Responses:

1. The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions.

2. The option may be settled in ordinary shares, American Depositary Shares ("ADSs") and/or cash at the election of the supervisory board.

3. Subject to adjustment such that the trading price of an ADS as of an exercise date does not exceed 800% of the grant date exercise price.

4. The exercise price of this option is EUR 93.35.

5. Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney

	/s/ Humza Bokhari, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does BioNTech (BNTX) Chief Commercial Officer Annemarie Hanekamp report in this Form 3?

Annemarie Hanekamp reports initial derivative equity holdings: an option over 8,838 ordinary shares and performance share units tied to 11,047 ordinary shares. These positions reflect compensation-related awards rather than open-market share purchases or sales, establishing her baseline equity exposure as an officer.

How do Annemarie Hanekamp’s BioNTech (BNTX) stock options vest and when can they be exercised?

Her option vests annually in equal installments over four years, beginning on the first anniversary of the grant date. It becomes fully exercisable four years after the grant date, subject to specified performance-based and other conditions that must be met before she can exercise all shares.

What are the key terms of the performance share units reported by BioNTech (BNTX) CCO?

Each performance share unit equals one ordinary share’s economic value and may settle in shares, ADSs, cash, or similar. The PSUs vest in equal annual installments over four years and become exercisable after four years, subject to market-based performance targets and continued service requirements.

What exercise price applies to Annemarie Hanekamp’s BioNTech (BNTX) stock option?

The option has an exercise price of EUR 93.35. A footnote states it is also subject to an adjustment so that the trading price of an American Depositary Share on an exercise date does not exceed 800% of the grant date exercise price level.

How can the equity awards in this BioNTech (BNTX) Form 3 be settled?

The option may be settled in ordinary shares, American Depositary Shares, and/or cash, at the supervisory board’s election. Each performance share unit similarly can settle in one ordinary share, one ADS, or a cash or equivalent payment equal to the share’s economic value.

Are the performance share units for BioNTech (BNTX) CCO tied to market performance?

Yes. The performance share units vest and become exercisable based on targets tied to the market price of BioNTech’s ordinary shares relative to the Nasdaq Biotechnology Index or a comparable successor index, along with the reporting person’s continued service during the vesting period.